Novartis | NOVN - SCHULD

Aktienkurs
113.34
Täglich Wechseln
-1.38 -1.20%
Monatlich
-5.41%
Jährlich
20.84%
Q2 Prognose
111.47




SCHULD Veränderung Datum
AbbVie USD 67.5B 67.5B 2025-12
Alcon AG USD 509M 4.74B 2025-12
Almirall EUR 342.86M 61.94M 2025-12
Amgen USD 54.59B 1.62B 2025-09
AstraZeneca USD 29.62B 3.01B 2025-12
Autolus Therapeutics Ltd USD 253.44M 8.84M 2025-03
Bayer EUR 39.39B 1.31B 2025-03
Biogen USD 6.29B 1.7M 2025-12
Bristol-Myers Squibb USD 51.04B 112M 2025-09
Eli Lilly USD 42.51B 2.6B 2025-09
Fresenius EUR 12.85B 778M 2025-06
Fresenius Medical Care EUR 10.8B 322.94M 2025-12
Galapagos EUR 7.5M 3.36M 2025-09
Genmab DKK 148M 5M 2025-06
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 17.72B 30M 2025-12
GRIFOLS EUR 8.82B 1.23B 2025-06
Hikma Pharmaceutical USD 1.56B 252M 2025-06
J&J USD 47.93B 2.14B 2025-12
Lonza CHF 4.71B 915M 2024-12
Merck EUR 12.1B 2.7B 2025-09
Merck USD 41.37B 5.97B 2025-09
Novartis USD 35.38B 2.74B 2025-12
Novartis USD 32.02B 615M 2025-09
Novo Nordisk DKK 118.72B 61.75B 2025-03
Orion EUR 305.4M 15.8M 2025-12
Pfizer USD 60.85B 78M 2025-09
Philips EUR 8.38B 41M 2025-09
Recordati EUR 2.5B 33.23M 2025-09
Regeneron Pharmaceuticals USD 2.71B 400K 2025-12
Roche Holding CHF 33.03B 1.41B 2025-06
Sanofi EUR 20.33B 1.43B 2025-12
UCB EUR 3.03B 12M 2024-12